Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03558087
Title Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Matthew Galsky
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.